NEW YORK — Zetta Genomics said on Tuesday that it has raised £2.5 million ($3.4 million) in seed funding.
The financing was led by Nina Capital with participation from Cambridge Enterprise and Apex Ventures.
Zetta, a spinout of the University of Cambridge, has developed a platform — called XetaBase — for the storage, management, and interrogation of large-scale genotypic and clinical data for precision medicine applications.
The UK-based company said it will use the seed money to expand its partnership network, open offices in Spain and the US, and increase its headcount in the areas of software, R&D, and product commercialization.
"Zetta Genomics re-imagines data to deliver a dynamic platform fit for the fast-emerging, fast-scaling, multi-petabyte environment," Zetta founder Ignacio Medina said in a statement. "In liberating genomic data, placing its power into the hands of researchers and clinicians, we will drive precision medicine's transformation into mainstream healthcare and life-changing patient benefit."
In mid-2020, Zetta began working with Genomics England and Sano Genetics to develop a software tool that will allow genomics research project participants with rare diseases to better self-report information and receive updates.